Skip to content
value.today

Tragara Pharmaceuticals Inc

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2005
Total raised
$29 M
6 rounds on record
Latest round
$2 M
Apr 2019
First round on record
Jan 2010
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tragara Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2019$2 MNo. 6$2 to $10 million

Tragara Pharmaceuticals Inc: Raise no. 6, Apr 2019

Investors in this round

3 investors had bought by the notice of Apr 24, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $12 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lynne R. Rollins · Executive Officer
  • Scott M. Megaffin · Executive Officer, Director
  • Tracy M. Lawhon · Executive Officer
  • Alain R. Schreiber · Director
  • Chris E. Christoffersen · Director
  • Dennis M. Podlesak · Director
  • Eckard R. Weber · Director
  • Grigory Borisenko · Director
  • Mauro Bove · Director
  • Thomas M. Estok · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lynne R. Rollins, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 24, 2019. Read the notice at the SEC.

equity, optionsSEC
Nov 2016$3 MNo. 5$2 to $10 million

Tragara Pharmaceuticals Inc: Raise no. 5, Nov 2016

Investors in this round

3 investors had bought by the notice of Nov 15, 2016: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis E. Bilski · Executive Officer
  • Thomas M. Estok · Executive Officer, Director
  • Tracy M. Parrott · Executive Officer
  • Alain P. Schreiber · Director
  • Eckard P. Weber · Director
  • Evgeny E. Zaytsev, M.D. · Director
  • Kim P. Kamdar · Director
  • Mauro E. Bove · Director
  • Ralph E. Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas M. Estok, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 15, 2016. Read the notice at the SEC.

equitySEC
Aug 2015$13 MNo. 4$10 to $50 million

Tragara Pharmaceuticals Inc: Raise no. 4, Aug 2015

Investors in this round

7 investors had bought by the notice of Sep 2, 2015: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$50,000
Paid to its own people
$900,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis E. Bilski · Executive Officer
  • Thomas M. Estok · Executive Officer, Director
  • Tracy M. Parrott · Executive Officer
  • Alain P. Schreiber · Director
  • Eckard P. Weber · Director
  • Evgeny E. Zaytsev, M.D. · Director
  • Kim P. Kamdar · Director
  • Mauro E. Bove · Director
  • Ralph E. Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas M. Estok, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 2, 2015. Read the notice at the SEC.

equitySEC
Jul 2015$1 MNo. 3Under $2 million

Tragara Pharmaceuticals Inc: Raise no. 3, Jul 2015

Investors in this round

5 investors had bought by the notice of Jul 17, 2015: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris M. LeMasters · Executive Officer
  • Thomas M. Estok · Executive Officer, Director
  • Tracy M. Parrott · Executive Officer
  • Alain P. Schreiber · Director
  • Eckard P. Weber · Director
  • Evgeny E. Zaytsev, M.D. · Director
  • Kim P. Kamdar · Director
  • Ralph E. Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas M. Estok, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 17, 2015. Read the notice at the SEC.

debt, optionsSEC
Jul 2012$4 MNo. 2$2 to $10 million

Tragara Pharmaceuticals Inc: Raise no. 2, Jul 2012

Investors in this round

4 investors had bought by the notice of Aug 8, 2012: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris M LeMasters · Executive Officer
  • Thomas M Estok · Executive Officer, Director
  • Tracy M Parrott · Executive Officer
  • Alain P. Schreiber · Director
  • Eckard P. Weber · Director
  • Kim P. Kamdar · Director
  • Ralph E. Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas M. Estok, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 8, 2012. Read the notice at the SEC.

debt, optionsSEC
Jan 2010$5 MNo. 1$2 to $10 million

Tragara Pharmaceuticals Inc: Raise no. 1, Jan 2010

Investors in this round

7 investors had bought by the notice of Feb 4, 2010: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas M. Estok · Executive Officer, Director
  • Alain B. Schreiber, M.D. · Director
  • Eckard B. Weber, M.D. · Director
  • Kim P. Kamdar, Ph.D. · Director
  • Ralph E. Christoffersen, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas M. Estok, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 4, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tragara Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Apr 2019).

    SEC Form D · Apr 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2019

That is all the official record says: Tragara Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Tragara Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tragara Pharmaceuticals Inc
NameRoleNamed in
Lynne R. RollinsExecutive officerApr 2019
Scott M. MegaffinExecutive officerApr 2019
Tracy M. LawhonExecutive officerApr 2019
Dennis E. BilskiExecutive officerNov 2016
Thomas M. EstokExecutive officerNov 2016
Tracy M. ParrottExecutive officerNov 2016
Chris M. LeMastersExecutive officerJul 2015
Chris M LeMastersExecutive officerAug 2012
Thomas M EstokExecutive officerAug 2012
Tracy M ParrottExecutive officerAug 2012
Alain R. SchreiberDirectorApr 2019
Chris E. ChristoffersenDirectorApr 2019
Dennis M. PodlesakDirectorApr 2019
Eckard R. WeberDirectorApr 2019
Grigory BorisenkoDirectorApr 2019
Mauro BoveDirectorApr 2019
Scott M. MegaffinDirectorApr 2019
Thomas M. EstokDirectorApr 2019
Alain P. SchreiberDirectorNov 2016
Eckard P. WeberDirectorNov 2016
Evgeny E. Zaytsev, M.D.DirectorNov 2016
Kim P. KamdarDirectorNov 2016
Mauro E. BoveDirectorNov 2016
Ralph E. ChristoffersenDirectorNov 2016
Thomas M EstokDirectorAug 2012
Alain B. Schreiber, M.D.DirectorFeb 2010
Eckard B. Weber, M.D.DirectorFeb 2010
Kim P. Kamdar, Ph.D.DirectorFeb 2010
Ralph E. Christoffersen, Ph.D.DirectorFeb 2010